Roche Sees Global Regulatory "Tightening," Not FDA "Slowdown"

The recent signs of tougher product reviews by global regulators reflect the need for better post-marketing surveillance in light of accelerated pharmaceutical development timelines, Roche suggested during an Aug. 16 media briefing in New York City.